Cesca Therapeutics to Present at the Inaugural Cell and Gene Exchange 2017
May 18 2017 - 8:33AM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced that Dr. Dalip Sethi, senior director of research
and development, will be presenting at the Cell and Gene Exchange
2017, taking place May 22-23 at the Ronald Reagan Building in
Washington, DC. Dr. Sethi will present at 2:45pm EDT on Tuesday,
May 23, 2017.
“As a leading developer of automated
technologies for cell-based therapeutics, we are delighted to take
part in the inaugural Cell and Gene Exchange partnering conference,
and look forward to presenting an overview of our broad
capabilities in this rapidly-growing field,” said Dr. Sethi.
“Cell-based therapies are at the foundation of many of today’s most
exciting clinical advancements. Our cutting-edge technology, which
is built on our flagship AutoXpress® processing platform, together
with our proprietary therapeutic development programs, have helped
make Cesca Therapeutics the partner of choice for many of the
leading medical institutions in the world.”
About the Inaugural Cell and Gene
ExchangeThe Cell and Gene Exchange is a leading partnering
forum focused on the regulatory, business, and patient advocate
communities in cell and gene therapy sectors.
About Cesca Therapeutics
Inc.Cesca is a leading regenerative medicine company that
develops, commercializes and markets a range of automated
technologies for cell-based therapeutics. Its device division,
ThermoGenesis, provides a full suite of solutions for automated
clinical biobanking, point-of-care applications, and automation for
immuno-oncology. Cesca is also leveraging its proprietary
AutoXpress® technology platform to develop autologous stem
cell-based therapies that address significant unmet needs in the
vascular, cardiology and orthopedic markets.
Cesca is an affiliate of the BoyaLife Group, a
China-based industry research alliance encompassing top research
institutions for stem cell and regenerative medicine.
Forward-Looking Statement
The statements contained herein may include
statements of future expectations and other forward-looking
statements that are based on management’s current views and
assumptions and involve known and unknown risks and uncertainties
that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. A
more complete description of risks that could cause actual events
to differ from the outcomes predicted by Cesca Therapeutics'
forward-looking statements is set forth under the caption "Risk
Factors" in Cesca Therapeutics’ annual report on Form 10-K and
other reports it files with the Securities and Exchange Commission
from time to time, and you should consider each of those factors
when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024